Latest news with #Nabota
Korea Herald
05-06-2025
- Business
- Korea Herald
Daewoong launches Nabota in Qatar, strengthens K-beauty in Middle East
Daewoong Pharmaceutical has officially launched its botulinum toxin product Nabota in Qatar, further strengthening its expansion into the Middle Eastern market, the company announced Thursday. The launch was marked by a symposium in Doha on May 30, where Nabota's entry into the Qatari market was formally announced. With this addition, Nabota is now available in all three key Gulf countries at the heart of the K-beauty trend: Qatar, Saudi Arabia and the United Arab Emirates. These nations represent high-potential markets, due to their high per capita income and growing interest in cosmetic and aesthetic procedures. Qatar, for example, had a per capita gross domestic product of around $80,000 in 2024, and demand for premium botulinum toxin products is rising quickly. According to Daewoong, the Qatar launch symposium attracted around 200 local medical professionals. 'Nabota is distinguished by its rapid and precise effects, making it the ideal product for Nabolift procedures that not only reduce wrinkles but also refine facial contours and expressions," Koo Bon-cheol, director of Naeum Dermatology and a featured speaker at the event, said. 'Given the limited number of botulinum toxin products currently registered in Qatar, the event highlighted the strong interest in Nabota among Middle Eastern health care providers,' Abdulkader Ramo, general practitioner from the UAE said. Meanwhile, Daewoong Pharmaceutical has also developed Nabolift, a proprietary technique that uses microinjections of botulinum toxin to promote lifting, reduce wrinkles and stimulate collagen production. The company plans to launch marketing campaigns across Qatar and the UAE that highlight differentiated procedures like the Nabolift, while strengthening its partnerships with local collaborators. 'The launch is meaningful in that it establishes Qatar as a new strategic foothold in the Middle East,' said Yoon Joon-soo, head of Daewoong's Nabota Business Division. 'We plan to further expand across the region by leveraging Nabota's high-quality performance and our exclusive treatment methods like Nabolift.'
Korea Herald
14-02-2025
- Business
- Korea Herald
Daewoong secures largest Latin America deal for Nabota
Daewoong Pharmaceutical announced Friday that it had signed a 180 billion won ($135 million) botulinum toxin export contract, marking the largest deal it has ever secured in the Latin American market. The company inked a five-year export contract for Nabota with its Brazilian partner, Moksha8 Pharmaceuticals, marking a tenfold increase from their 2018 deal worth 18 billion won. Brazil is the world's third-largest medical aesthetics market, following the United States and China, and is also known as the leading country in Latin America for botulinum toxin sales. According to market research firm Mordor Intelligence, the Brazilian botulinum toxin market has been growing steadily at an annual rate of 9.7 percent. This year, it is expected to reach some $228 million. Moksha8 Pharmaceuticals plans to strengthen its presence in Brazil with the Nabota 200-unit product, a high-dose version that obtained approval last month. Daewoong Pharmaceutical expects that the product's launch will broaden customer options for large hospitals and clinics with a high patient volume, as they favor high-dose products. Meanwhile, the company aims to leverage its success in Brazil to strengthen Nabota's brand recognition across Latin America. The company's botulinum toxin has already made successful inroads into major South American markets such as Argentina, Chile and Peru. Globally, Nabota has received product approval in 69 countries and established partnerships in over 80 countries. Nabota is a premium botulinum toxin manufactured using Korea and US-patented Hi-Pure Technology, and a vacuum-drying process, ensuring a high purity of over 98 percent. It delivers fast and precise effects while minimizing the occurrence of inactive toxins that could cause resistance. "The contract demonstrates Nabota's global competitiveness in the botulinum toxin market," said Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division. 'We will further expand our presence in Brazil while actively targeting key Latin American markets such as Argentina, Chile and Peru.'
